Wei Hua, MD, PhD, FHRS, Deputy Director of Cardiac Arrhythmia Center, Fu Wai Hospital, Chinese Academy of Medical Sciences, National Heart Center, China.
Highlights of clinical Skill in Cardiac Pacing and Electrophysiology:
Pacemaker implantation (over 3000 pacemakers)
CRT device implantation (over 300 devices)
Implantable Cardioversion Defibrillator (ICD) implantation (over 400 devices)
Radiofrequency catheter ablation
Implanted the most CRT and ICD devices in China individually and help many of Hospitals in China started to carried out ICD and CRT therapy
Ph.D., Cardiac Electrophysiology, Graduate School of Peking Union Medical College, Beijing, China, 2003
M.D., Shanghai Medical University, Shanghai, China, 1985
Training in oversea
1994.2-1996.2 Clinical Fellow in cardiac pacing and electrophysiology, Department of Cardiology, The Royal Melbourne Hospital, Australia
2007,11-12 Visiting Scholar, Department of Cardiology, Mayo Clinic, United .States
Memberships and others
Vice President of Chinese Society of Cardiac Pacing and Electrophysiology (CSPE) and chairman of Cardiac Pacing Committee of CSPE
Chinese Association of Medicine
Chinese Society of Biomedical Engineering
Fellow of Heart Rhythm Society,(FHRS)
European Heart rhythm Association (EHRA)
New York Academy of Sciences
Member of organization committee of The Second APHRS Scientific Session (APHRS 2009)
Vice Editor in-Chief of News in heart rhythm
Research: ( PI)
The epidemiology and prevention of sudden cardiac death in China (The tenth five years national research project)
The prevention of sudden cardiac death using Implantable cardioverter defibrillators (The tenth five years national research project)
Computer simulation of heart disease（National Key Basic Research Program 973 sub-project）
CRT in patients with heart failure after pacemaker implantation: mechanisms and hemodynamic study（National Natural Science Foundation of China）
The Quik Opt Timing for CRT in patients with Congestive heart failure ( multi-center study)
CRT in patients with pacemaker and Congestive heart failure ( multi-center study)
The clinical study of the effect of Nifekalant on the refractory ventricular tachycardia ( multi-center study)
As first author
1 Hua W, Zhang LF, Wu YF, et al. Incidence of sudden cardiac death in China: analysis of 4 regional populations. J Am Coll Cardiol 2009; 54(12): 1110-8.
2 Hua W.Cardiac resynchronization therapy for chronic heart failure in China: guideline and practice (Editorial). Chin Med J 2010, 123(17): 2293-2294.
3 Hua W, Qiao Q, Ding LG, et al. Predictors of super-response to cardiac resynchronization therapy. Chin J Cardiac Arrhyth 2010, 14(6): 430-432.
4 Hua Wei, Ding Li-gang, Zhang Shu, et al. Usefulness of previsualization of the cardiac venous system by 64-slice computed tomography in patients with heart failure underwent cardiac resynchronization therapy. Chin J Cardiol 2010, 38(7): 610-613.
5 Hua W, Ding LG, Zhang S, et al. Home monitoring in cardiac resynchronization therapy. Chin J Cardiac Arrhyth, 2010, 14(3): 169-171.
6 Hua W, Zhang S, Niu HX, et al. Primary and secondary prevention of sudden cardiac death with implantable cardioverter defibrillator—Analysis the indications of ICD in 31 hospital patients. Chin J Cardiac Arrhyth, 2010, 14(1): 9-11.
7 Hua W, Wang J, Wang FZ, et al. Initial experience in treating ventricular tachycardia with nifekalant hydrochloride. Chin J Cardiac Arrhyth, 2008, 12(1): 8-11.
8 Hua W, Ding LG, Zhang S, et al. Effect of VVI pacing on cardiac function and the occurrence of atrial fibrillation in patients with VVI pacemaker replantation. Chin J Cardiac Arrhyth, 2007,11(5): 346-348.
9 Hua W, Niu HX, Wang FZ,etal. Short-term effect of cardiac resynchronization therapy in patients with ischaemic or nonischaemic cardiomyopathy. Chin Med J. 2006; 119(18):1507-10
As corresponding author:
1 Wang J, Hua W, Zhu J, et al. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation. Chin Med J . 2010;123(15):2028-33.
2 Qiao Q, Hua W, Zhang S. Preimplant left ventricular end-diastolic dimension and body weight independently associate with paced QRS duration in patients receiving right ventricular apical pacing for complete atrioventricular block. Clin Cardiol. 2010;33(11):715-9.
3 Qiao Q, Ding LG, Hua W, et al. QRS duration change immediately after cardiac resynchronization therapy in predicting non-response and super-response. Chin J Cardiac Arrhyth, 2010, 14(3): 172-175.
4 Wang J, Hua W, Zhu J, et al. The efficacy and safety of long-term nifekalant hydrochloride for treating patients with sustained ventricular tachycardia. Chin J Cardiac Arrhyth, 2010,14(1):34-38.
5 Ding L, Hua W, Zhang S, et al. Improvement of P wave dispersion after cardiac resynchronization therapy for heart failure. J Electrocardiol. 2009;42(4):334-8.
6 Ding LG, Hua W, Zhang S, et al. Decrease of plasma BNP as a predictor of improvement of CRT for heart failure. Chin Med J . 2009,617-621.
7 Ding L, Hua W, Niu H,etal. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace. 2008;10(9):1034-41.
8 Niu HX, Hua W, Zhang S,etal. Optimized cardiac resynchronization therapy in patients with congestive heart failure. Chin Med J . 2007;120(7):605-7.
9 Niu H, Hua W, Zhang S,etal. Prevalence of dyssynchrony derived from echocardiographic criteria in heart failure patients with normal or prolonged QRS duration. Echocardiography. 2007;24(4):348-52.
10 Niu HX, Hua W, Zhang S, etal. Assessment of cardiac function and synchronicity in subjects with isolated bundle branch block using Doppler imaging. Chin Med J . 2006;119(10):795-800.
11 Niu HX, Hua W, Wang FZ,etal. Complications of cardiac resynchronization therapy in patients with congestive heart failure. Chin Med J . 2006;119(6):449-53.